EVLO (Evelo Biosciences) Forward PE Ratio: 0.00 (As of Jul. 11, 2026)


What is Evelo Biosciences Forward PE Ratio?

Evelo Biosciences EVLO Forward PE Ratio is 0.00 as of Jul. 11, 2026.

Evelo Biosciences's Forward PE Ratio for today is 0.00.

Evelo Biosciences's PE Ratio without NRI for today is 0.00.

Evelo Biosciences's PE Ratio (TTM) for today is 0.00.

Evelo Biosciences  (OTCPK:EVLO) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Evelo Biosciences Forward PE Ratio Related Terms

Evelo Biosciences Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences Forward PE Ratio Chart

Evelo Biosciences Annual Data
Trend
Forward PE Ratio

Evelo Biosciences Quarterly Data
Forward PE Ratio

EVLO vs IMNN, EDSA, TMBR: Forward PE Ratio Comparison

For the Biotechnology subindustry, Evelo Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evelo Biosciences Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's Forward PE Ratio falls into.


Evelo Biosciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Evelo Biosciences (EVLO) has a Forward PE Ratio of 0.00 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Evelo Biosciences and its competitors.
Is Evelo Biosciences' Forward PE Ratio too high?
Evelo Biosciences' current Forward PE Ratio is 0.00.
How does Evelo Biosciences' Forward PE Ratio compare to IMNN and EDSA?
Evelo Biosciences' Forward PE Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median Forward PE Ratio is 21.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.90, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Evelo Biosciences and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evelo Biosciences's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current Forward PE Ratio is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.